BRAIN TUMOR BIOREPOSITORY, HISTOPATHOLOGY, AND IMMUNOLOGIC MONITORING

脑肿瘤生物样本库、组织病理学和免疫学监测

基本信息

批准号：
8376997
负责人：
ROGER E MCLENDON
金额：
$ 18.27万
依托单位：
DUKE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/8376997
关键词：
Adverse event Autopsy Bioinformatics Biological Assay Biopsy Blood Brain Brain Neoplasms Cancer Vaccines Cataloging Catalogs Centers for Disease Control and Prevention (U.S.)Chondroitin Sulfate Proteoglycan Classification Clinical Clinical Research Clinical Trials Collaborations Cytogenetics DNA Data Data Set Databases Development Diagnostic Doctor of Medicine Doctor of Philosophy Eligibility Determination Enrollment Epidermal Growth Factor Receptor Epilepsy Flow Cytometry Freezing Funding Genetic Glioblastoma Glioma Grant Histologic Histopathology Housing Human Human Herpesvirus 4 Human Resources Immune response Immunologic Monitoring Immunologics Immunology Immunophenotyping In Vitro Individual Institutional Review Boards Instruction Laboratories Link Lymphocyte Malignant Glioma Malignant neoplasm of brain Manuscripts Measures Methyltransferase Modeling Molecular National Institute of Allergy and Infectious Disease National Institute of Neurological Disorders and Stroke Nautilus Neoplasm Metastasis Outcome Pathologic Patients Peer Review Performance Peripheral Population Primary Neoplasm Principal Investigator Process Program Evaluation RNA Relative (related person)Research Research Personnel Resistance Sampling Serum Somatic Cell Sorting - Cell Movement Source Specimen Staining method Stains Standardization T-Lymphocyte TNFRSF5 gene Testing Therapeutic Tissue Banking Tissue Banks Tissues Toxic effect Training Translations Trauma Tumor Tissue United States National Institutes of Health Vaccines Work Writing base biobank brain tissue cytokine disorder control experience immune function in vivo neurosurgery novel peripheral blood pre-clinical preclinical study programs repository response success treatment response tumor working group

项目摘要

Core B. Brain Tumor Biorepository, Histopathology, and Immunologic Monitoring Core. Roger McLendon, M.D., Core Leader The access to appropriately procured tissue (brain tumor, normal brain, and matched somatic cells) has been fundamental to the success of this NINDS Specialized Research Center on Primary and Metastatic Tumors of the CMS since its inception 25 years ago. This Biorepository has successfully obtained and sorted brain tumor tissue and matched peripheral somatic cells from more than 800 individual brain tumor patients with a net accumulation of more than 6,750 blocks of gliomas tissue. The Duke Immunologic Monitoring component of this Core will provide a variety of standard and in-house developed polychromatic flow cytometric assays of immune function, including intracellular cytokine staining and degranulation within a broad range of phenotypically-defmed T-cell populations on patients in Project 1. The Database component of this Core will store data from the genetic, cytogenetic, immunohistochemical, histologic and diagnostic analyses of all banked brain tumor tissues as well as normal brain samples in the Biorepository and furnish data to researchers requiring these data working in Projects 1, 2, and 3 and the IND, Regulatory, and Bioinformatics Core under Duke IRB oversight. This Core's Specific Aims will support the clinical and preclinical studies described in Projects 1, 2, and 3: 1) Provide and maintain a clinically annotated and catalogued biorepository of human brain tumor tissue, normal human brain tissue, and matched somatic cells from all brain tumor patients in clinical trials in Projects 1, 2, and 3; The Repository has a Nautilus database that will be linked to a clinical Oracle database in which all patients on a clinical trial in Projects 1, 2, and 3 will be entered; 2) Maintain access for scientific questions relative to Projects 1, 2, and 3 for the more than 800 brain tumor patient specimens and their matched somatic ceils entered into this Repository since the inception of this P50 grant in the early 1980s; 3) Provide integrated pathologic, histologic, immunohistochemical, and molecular diagnostic studies for Projects 1, 2, and 3, which will be entered into the Biorepository Nautilus database and linked to the Oracle clinical database for each patient; 4) Provide comprehensive immunologic monitoring of patients enrolled in clinical trials in Projects 1, 2, and 3, using highly standardized/validated state-of-the-art flow cytometry-based assays. RELEVANCE (See instructions): The availability of brain tumor tissue is necessary to determine the eligibility of patients for the clinical trials. Most of the new treatments depend on demonstrating specific molecules in each patient's brain tumor in order to enroll the patient in the appropriate clinical trial. The vaccine studies for malignant gliomas require immunologic monitoring of the responses to the vaccine treatment.

核心 B. 脑肿瘤生物样本库、组织病理学和免疫监测核心。罗杰·麦克伦登, 医学博士，核心领导者获得适当获得的组织（脑肿瘤、正常大脑和匹配的体细胞）已经是 NINDS 原发性和转移性专业研究中心成功的基础肿瘤CMS自25年前成立以来。该生物样本库已成功获得从 800 多个脑肿瘤个体中分选脑肿瘤组织并匹配外周体细胞患者的神经胶质瘤组织净积累超过 6,750 块。杜克大学免疫学该核心的监控组件将提供各种标准和内部开发的多色免疫功能的流式细胞术检测，包括细胞内细胞因子染色和脱颗粒项目 1 中患者的广泛表型定义的 T 细胞群。数据库该核心的组件将存储来自遗传、细胞遗传学、免疫组织化学、组织学和对生物样本库中所有储存的脑肿瘤组织以及正常脑样本进行诊断分析并向项目 1、2 和 3 以及 IND、监管机构中需要这些数据的研究人员提供数据和生物信息学核心在杜克大学 IRB 的监督下。该核心的具体目标将支持项目 1、2 和 3 中描述的临床和临床前研究： 1）提供并维护一个经过临床注释和编目的人脑肿瘤组织生物样本库，正常人脑组织以及所有脑肿瘤患者的匹配体细胞在临床试验中项目 1、2 和 3；该存储库有一个 Nautilus 数据库，该数据库将链接到临床 Oracle 数据库其中所有参加项目 1、2 和 3 临床试验的患者都将被纳入； 2) 保持科学访问针对 800 多个脑肿瘤患者标本及其与项目 1、2 和 3 相关的问题自 20 世纪 80 年代初 P50 资助启动以来，匹配的体细胞就进入了该存储库； 3）提供综合病理学、组织学、免疫组织化学和分子诊断研究项目 1、2 和 3，将输入 Biorepository Nautilus 数据库并链接到 Oracle 每个患者的临床数据库； 4) 为入组患者提供全面的免疫学监测项目 1、2 和 3 中的临床试验使用高度标准化/经过验证的最先进的流式细胞术化验。相关性（参见说明）：脑肿瘤组织的可用性对于确定患者参加临床试验的资格是必要的。大多数新疗法依赖于在每个患者的脑肿瘤中证明特定分子以便让患者参加适当的临床试验。恶性神经胶质瘤的疫苗研究需要对疫苗治疗反应的免疫学监测。